Corbus Pharmaceuticals Holdings Inc CRBP:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
after hours iconAfter Hours: Last | 4:09 PM EDT
37.16UNCH (UNCH)
Volume
3,351
Close
37.16quote price arrow down-3.96 (-9.63%)
Volume
416,480
52 week range
3.03 - 49.87
Loading...
  • Open41.12
  • Day High41.12
  • Day Low36.09
  • Prev Close41.12
  • 52 Week High49.87
  • 52 Week High Date03/13/24
  • 52 Week Low3.03
  • 52 Week Low Date11/13/23

Key Stats

  • Market Cap390.449M
  • Shares Out10.51M
  • 10 Day Average Volume0.23M
  • Dividend-
  • Dividend Yield-
  • Beta2.44
  • YTD % Change515.23

KEY STATS

  • Open41.12
  • Day High41.12
  • Day Low36.09
  • Prev Close41.12
  • 52 Week High49.87
  • 52 Week High Date03/13/24
  • 52 Week Low3.03
  • 52 Week Low Date11/13/23
  • Market Cap390.449M
  • Shares Out10.51M
  • 10 Day Average Volume0.23M
  • Dividend-
  • Dividend Yield-
  • Beta2.44
  • YTD % Change515.23

RATIOS/PROFITABILITY

  • EPS (TTM)-10.38
  • P/E (TTM)-3.58
  • Fwd P/E (NTM)-7.15
  • EBITDA (TTM)-44.436M
  • ROE (TTM)-341.98%
  • Revenue (TTM)-
  • Gross Margin (TTM)-
  • Net Margin (TTM)-36,090.23%
  • Debt To Equity (MRQ)-234.75%

EVENTS

  • Earnings Date05/07/2024(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Corbus Pharmaceuticals Holdings Inc

 

Profile

MORE
Corbus Pharmaceuticals Holdings, Inc. is a precision oncology company with a diversified portfolio. The Company's pipeline is comprised of two experimental drugs targeting solid tumors: CRB-701, which is an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload and CRB-601, which is an anti-integrin monoclonal antibody that blocks the activation of TGFβ expressed on cancer cells. Its pipeline also includes CRB-913...
Alan Holmer J.D.
Independent Chairman of the Board
Yuval Cohen Ph.D.
Chief Executive Officer, Director
Sean Moran CPA
Chief Financial Officer
Address
500 River Ridge Drive
Norwood, MA
02062
United States

Top Peers

SYMBOLLASTCHG%CHG
PEPG
PepGen Inc
11.50-1.09-8.66%
REPL
Replimune Group Inc
7.21+0.06+0.84%
OCS
Oculis Holding AG
12.04+0.04+0.33%
LRMR
Larimar Therapeutics Inc
7.05-0.19-2.62%
STTK
Shattuck Labs Inc
10.02+1.04+11.58%